Option chain shows key data for LakeShore Biopharma's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for LakeShore Biopharma.

LakeShore Biopharma (NASDAQ:LSB) Stock, Option Chain

LakeShore Biopharma

LakeShore Biopharma Co Ltd is a biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. The company operates in China, the United States, Singapore, and the Philippines.

LakeShore Biopharma Co., Ltd - Ordinary Shares

LakeShore Biopharma Co Ltd

Lake Shore Bancorp Inc

LSB Industries Inc

Chain Bridge Bancorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CBNA#NYSE">CBNA</a>) reported quarterly earnings of $0.59 per share which beat the analyst consensus estimate of $0.55 by 7.27 percent.

Earnings

Earnings Beats

News

CBNA

Chain Bridge Bancorp Q4 2024 GAAP EPS $0.59 Beats $0.55 Estimate

Paragon 28 has announced net revenue for the full year of 2024 to be in a range of $255.9 to $256.2 million, representing 18.2% to 18.4% reported growth over the prior fiscal year.&nbsp;
Zimmer Biomet expects the proposed transaction, considering the impact of financing, to be approximately 3% dilutive to adjusted earnings per share in 2025, about 1% dilutive to 2026 adjusted earnings per share and accretive to adjusted earnings per share within 24 months of deal close.
Zimmer Biomet plans to fund the proposed transaction through a combination of cash on the balance sheet and other available debt financing sources. Zimmer Biomet expects to maintain a strong balance sheet and to continue to support its stated capital allocation priorities.

Zimmer Biomet Expects Proposed Paragon 28 Transaction To Immediately Accelerate Revenue Growth And To Be Approximately 3% Dilutive To Adjusted EPS In 2025

Paragon 28 shareholders will also receive a non-tradeable contingent value right (CVR) entitling the holder to receive up to $1.00 per share in cash if certain revenue milestones are achieved.&nbsp;
The CVR will be payable in whole or in part if net sales exceed $346 million up to $361 million (with the CVR payments calculated linearly between $0.00 and $1.00 if net sales are between $346 million and $361 million) during Zimmer Biomet's fiscal year 2026.&nbsp;
The board of directors of each of Zimmer Biomet and Paragon 28 has unanimously approved the proposed transaction.
 &nbsp;

Zimmer Biomet To Acquire Paragon 28 For Upfront Payment Of $13.00 Per Share In Cash, Corresponding To An Equity Value Of $1.1B And Enterprise Value Of $1.2B

Jones Trading analyst Soumit Roy initiates coverage on OnKure Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKUR#NASDAQ">OKUR</a>) with a Buy rating and announces Price Target of $32.

Price Target

Initiation

Analyst Ratings

OKUR

Jones Trading Initiates Coverage On OnKure Therapeutics with Buy Rating, Announces Price Target of $32

Jefferies analyst Rob Dickerson maintains WK Kellogg (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KLG#NYSE">KLG</a>) with a Hold and lowers the price target from $19 to $16.

Jefferies Maintains Hold on WK Kellogg, Lowers Price Target to $16

The Food and Drug Administration on Tuesday approved Ozempic, the weight loss drug made by Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), for the treatment of chronic kidney disease in patients who also <a href="https://www.benzinga.com/25/01/42875977/novo-nordisk-seeks-to-strengthen-its-obesity-pipeline-with-back-to-back-two-biobuck-deals">have type 2 diabetes. </a>
The Details: According to the Centers for Disease Control and Prevention, more than 35.5 million Americans have chronic kidney disease, often as a complication of type 2 diabetes. The new FDA approval allows for further expansion of Ozempic's use and potential coverage by health insurance plans.&nbsp;
Read Next:<a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/01/43254018/sofi-stock-falls-on-soft-guidance-despite-strong-quarter-with-record-member-growth-loan-originations-analyst"> SoFi Stock Falls On Soft Guidance Despite &#8216;Strong Quarter&#8217; With Record Member Growth, Loan Originations: Analyst&nbsp;</a>
The FDA approval "allows us to more broadly address conditions within cardiovascular-kidney-metabolic syndrome, which affects millions of adults and could have serious consequences if left untreated," Anna Windle, a senior vice president at Novo Nordisk, said in a statement Tuesday, per a Bloomberg <a href="https://www.bloomberg.com/news/articles/2025-01-28/novo-s-ozempic-notches-approval-for-kidney-disease-widening-use?sref=TBDibEcD">report</a>.&nbsp;
Ozempic and other diabetes drugs known as GLP-1s have become popular and also well-known for their high cost.&nbsp;
Earlier in January, Novo Nordisk's diabetes and weight loss drugs, Ozempic, Rybelsus, and Wegovy were all added to the U.S. Department of Health and Human Services list of drugs covered under Medicare Part D that<a href="https://www.benzinga.com/25/01/43062779/popular-ozempic-wegovy-selected-for-next-round-of-medicare-drug-price-negotiations"> have been selected</a> for mandated price negotiations in order to reduce <a href="https://www.benzinga.com/general/biotech/24/08/40534249/novo-nordisks-ozempic-might-be-among-2027-medicare-price-negotiation-targets">prescription drug costs</a>.
The negotiations will take place in 2025, with the new prices slated to take effect in 2027.
NVO Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Novo Nordisk shares ended Tuesday's session down 2.65% at $85.19.&nbsp;
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/25/01/43287988/microsoft-q2-preview">Microsoft Q2 Earnings Preview: Street &#8216;Too Optimistic&#8217; On Near-Term AI Returns?&nbsp;</a></li>
</ul>
Photo: Shutterstock

Biotech

Health Care

Movers

Trading Ideas

General

Ozempic Receives FDA Approval To Treat Kidney Disease

Trading Halt: Halt status updated at 5:50:00 PM ET: Quotation Resumption: News and Resumption Times

Finward Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FNWD#NASDAQ">FNWD</a>) reported quarterly earnings of $0.49 per share which beat the analyst consensus estimate of $0.20 by 145 percent. This is a 40 percent increase over earnings of $0.35 per share from the same period last year. The company reported quarterly sales of $16.34 million which beat the analyst consensus estimate of $16.00 million by 2.12 percent. This is a 5.75 percent increase over sales of $15.45 million the same period last year.

FNWD

Finward Bancorp Q4 2024 GAAP EPS $0.49 Beats $0.20 Estimate, Sales $16.34M Beat $16.00M Estimate

Compass Point analyst Giuliano Bologna upgrades Affirm Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>) from Sell to Neutral and raises the price target from $20 to $61.

Upgrades

AFRM

Compass Point Upgrades Affirm Holdings to Neutral, Raises Price Target to $61

The options include a possible sale of the company, business combination, sale of all or part of the Company's assets, licensing of assets, restructuring, or other strategic action.

23andMe Reveals Process To Explore Strategic Alternatives

Compass Point analyst Joe Flynn initiates coverage on Applied Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLD#NASDAQ">APLD</a>) with a Buy rating and announces Price Target of $10.

APLD

Compass Point Initiates Coverage On Applied Digital with Buy Rating, Announces Price Target of $10

Synaptics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYNA#NASDAQ">SYNA</a>) shares are rising in extended trading Tuesday after the company signed a <a href="https://www.benzinga.com/pressreleases/25/01/g43286953/synaptics-accelerates-edge-ai-strategy-with-new-broadcom-agreement">licensing agreement with Broadcom Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>)</a>.
What Happened: After the market close on Tuesday, Synaptics announced it&#8217;s accelerating its Edge <a href="http://benzinga.com/topic/ai">AI</a> strategy through a definitive licensing agreement with Broadcom.
The agreement includes Wi-Fi&nbsp;8, ultra-wideband (UWB), Wi-Fi 7, advanced Bluetooth and GPS/GNSS products and technology for IoT and the Android ecosystem.
&#8220;Our wireless technology and capabilities are cornerstones of our success in IoT markets,&#8221; said Michael Hurlston, president and CEO of Synaptics. 
&#8220;We are now developing this expertise to enable ecosystems with centralized control and seamless connectivity to a rapidly growing array of Edge AI devices. Our platform history, proven track record, and strategy uniquely position us to integrate Broadcom&#8217;s technology and fully deliver on the potential of IoT connectivity.&#8221;
Check This Out: <a href="https://www.benzinga.com/general/restaurants/25/01/43288533/starbucks-q1-earnings-revenue-beat-eps-beat-memberships-up-1-positive-response-to-turnaround-efforts">Starbucks Q1 Earnings: Revenue Beat, EPS Beat, Memberships Up 1%, &#8216;Positive Response&#8217; To Turnaround Efforts</a>
Synaptics said the deal is expected to add&nbsp;at least $40 million in annualized sales. The company also expects the transaction to be immediately accretive to adjusted earnings per share. 
The all-cash transaction is expected to close on Jan. 30. Financing details were not provided, but Synaptics said it will provide more information on the transaction when it reports <a href="https://www.benzinga.com/calendars/earnings">second-quarter earnings</a> on Feb. 6. 
Analysts currently expect Synaptics to report earnings of 86 cents per share and revenue of $265.14 million for the second quarter, according to <a href="http://pro.benzinga.com">Benzinga Pro</a> estimates.
SYNA Price Action: Synaptics shares were up 5.13% in after-hours, trading at $84.66 at the time of publication Tuesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
This illustration was generated using artificial intelligence via Midjourney.

Contracts

After-Hours Center

Tech

AVGO

SYNA

Synaptics Stock Climbs On Broadcom Deal Focused On Edge AI

MGNI

Magnite Says Working With Sky New Zealand To Power Programmatic Advertising On Sports Streaming Platform, Sky Sport Now

Compass Point analyst David Rochester downgrades Synchrony Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYF#NYSE">SYF</a>) from Buy to Neutral and announces $70 price target.

Downgrades

Compass Point Downgrades Synchrony Finl to Neutral, Announces $70 Price Target

Through this contract, Planet joins the Copernicus Contributing Missions, officially contributing commercial satellite data alongside ESA's Sentinel satellite data to the Copernicus services.

Planet Labs Germany GmbH Signs Multi-year Contract With The European Space Agency

CIBC analyst Paul Holden maintains Sun Life Financial (TSX:<a class="ticker" href="https://www.benzinga.com/stock/SLF#TSX">SLF</a>) with a Outperformer and raises the price target from C$96 to C$97.

TSX:SLF

CIBC Maintains Outperformer on Sun Life Financial, Raises Price Target to C$97

It is payable March 17, 2025, to shareholders of record at the close of business on March 3, 2025.

Dividends

Stifel Financial Boosts Quarterly Common Stock Cash Dividend By 10% From $0.42 To $0.46 Per Share

This settlement concludes Aspen's legal action against AMA regarding the unauthorized sale of infringing aerogel insulation materials in Europe.

Legal

ASPN

Aspen Aerogels Reaches Agreement To Resolve Its Patent Dispute With AMA; No Terms Disclosed

CIBC analyst Paul Holden maintains Manulife Financial (TSX:<a class="ticker" href="https://www.benzinga.com/stock/MFC#TSX">MFC</a>) with a Neutral and raises the price target from C$46 to C$47.

TSX:MFC

CIBC Maintains Neutral on Manulife Financial, Raises Price Target to C$47

Primis Finl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRST#NASDAQ">FRST</a>) reported quarterly losses of $(0.65) per share which missed the analyst consensus estimate of $0.11 by 690.91 percent. This is a 285.71 percent decrease over earnings of $0.35 per share from the same period last year. The company reported quarterly sales of $39.30 million which beat the analyst consensus estimate of $24.78 million by 58.63 percent. This is a 0.17 percent increase over sales of $39.24 million the same period last year.

Comments

LakeShore Biopharma

LakeShore Biopharma (LSB) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga